公开(公告)号：EP1526871A1

公开(公告)日：2005-05-04

申请号：EP03766387.9

申请日：2003-07-31

申请人： Novartis AG

发明人： AZRIA, Moise ,  BATEMAN, Simon, David ,  MCLEOD, James, F.

IPC分类号： A61K47/18 ,  A61K38/23

CPC分类号： A61K31/195 ,  A61K9/19 ,  A61K9/2013 ,  A61K9/2027 ,  A61K38/23 ,  A61K47/183

摘要： Disclosed is a particular method of orally administering pharmaceutical compositions comprising calcitonin in combination with oral delivery agents, prior to the consumption of food in humans, and a method of treatment of disorders responsive to the action of calcitonin employing such method of administration; also oral calcitonin pharmaceutical compositions with particular ratios of the amount of oral delivery agent to the amount of calcitonin.

公开(公告)号：EP1499361A1

公开(公告)日：2005-01-26

申请号：EP03720497.1

申请日：2003-04-17

申请人： Novartis AG ,  Novartis Pharma GmbH

发明人： SZENTE, Lajos ,  SZEJTLI, Jozsef ,  KIS, György, Lajos ,  SCHOCH, Christian

IPC分类号： A61K47/36 ,  A61K47/40 ,  A61K47/18 ,  A61K9/70 ,  A61K9/20

CPC分类号： A61K9/0024 ,  A61K9/7015 ,  A61L27/20 ,  A61L27/54 ,  A61L2300/602 ,  A61L2300/802 ,  C08L5/16

摘要： The present invention relates to novel materials, particularly biomaterials, in form of a precipitate, comprising at least an anionic polymeric component which is as such soluble in water and an amphiphilic ammonium-type component, which precipitate is obtainable by a process including the following steps: contacting the anionic polymeric component and an cylcodextrin component in an aqueous medium, and adding to the mixture obtained in step 1 said amphiphilic ammonium-type component, wherein said components are present in amounts effective to form said precipitate, and preferably to corresponding precipitates additionally comprising said cycxlodextrin component. Both types of precipitates may optionally comprise one or more further components. The precipitates are particularly useful as controlled-release depot formulations suitable for long-lasting delivery of said further components. The further components incorporated into the precipitates can be pharmaceutical compounds, pesticides, agrochemicals, colorants, diagnostics, enzymes, foodstuffs etc.

公开(公告)号：EP1553957A1

公开(公告)日：2005-07-20

申请号：EP03750714.2

申请日：2003-10-14

申请人： Novartis AG ,  Novartis Pharma GmbH

发明人： PRESCOTT, Margaret, Forney

IPC分类号： A61K31/663 ,  A61P9/10

CPC分类号： A61K31/675 ,  A61K9/5026 ,  A61K9/5073 ,  A61K9/7053 ,  A61K31/663 ,  A61L31/10 ,  A61L31/16 ,  A61L2300/112 ,  A61L2300/45 ,  A61L2400/02

摘要： A method for the treatment of atherosclerosis, in particular atherosclerotic/valve calcification and plaque rupture/stroke, in a patient in need of such treatment, e.g. a patient with aterial or valve calcification, which comprises administering an effective amount of a bisphosphonate, e.g. zoledronic acid or salts or hydrates thereof, to the patient. Especially the invention relates to the local administration the bisphosphonate and to a device, e.g. stent adapted for such local administration.

公开(公告)号：EP1551827A1

公开(公告)日：2005-07-13

申请号：EP03798931.6

申请日：2003-10-06

申请人： Novartis AG ,  Novartis Pharma GmbH

发明人： ALBERT, Rainer ,  COOKE, Nigel, Graham ,  THOMA, Gebhard ,  STREIFF, Markus

IPC分类号： C07D401/14 ,  C07D211/58 ,  A61K31/4545

CPC分类号： C07D401/14 ,  C07D211/58 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14

摘要： Disclosed are compounds of formula (I) wherein R1, R2, R3 and X are as defined herein, in free or salt form, which are useful as CCR5 inhibitors, e.g. in the prevention or treatment of disorders mediated by interactions between chemokine receptors and their ligands.

公开(公告)号：EP1540340A2

公开(公告)日：2005-06-15

申请号：EP03757829.1

申请日：2003-09-12

申请人： Novartis AG ,  Novartis Pharma GmbH

发明人： MÜLLER, Achim ,  SCHMIEDER, Roland ,  SCHMID, Katharina

IPC分类号： G01N33/487 ,  A61B3/10 ,  A61B10/00

CPC分类号： G01N33/487 ,  A61B2010/0067

摘要： The present invention concerns a process for analyzing an analyte in a hydrogel contact lens following its wear on the eye, comprising the steps of (a) physically or chemically inducing a volume reduction of the hydrogel contact lens and thereby squeezing the analyte out of the polymer material making up the contact lens and (b) feeding the analyte obtained according to step (a) into an analyzer. The process of the invention provides a new concept for noninvasively measuring various analytes occurring in the tear fluid that is comfortable to the user.

公开(公告)号：EP1542669A1

公开(公告)日：2005-06-22

申请号：EP03797314.6

申请日：2003-09-19

申请人： Novartis AG

发明人： TROUP, John, P. ,  WOLFE, Robert, R.

IPC分类号： A61K31/195 ,  A61P35/00 ,  A23L1/29

CPC分类号： A23L1/293 ,  A23L2/52 ,  A23L33/115 ,  A23L33/17 ,  A23L33/175 ,  A23L33/30 ,  A23L33/40 ,  A23V2002/00 ,  A61K31/195 ,  A61K31/198 ,  A61K31/405 ,  A61K31/4172 ,  A61K2300/00 ,  A23V2250/5114 ,  A23V2250/15 ,  A23V2250/704 ,  A23V2250/714 ,  A23V2250/7106 ,  A23V2250/702 ,  A23V2250/72 ,  A23V2250/1882 ,  A23V2250/712 ,  A23V2250/54246 ,  A23V2250/5046 ,  A23V2250/0606 ,  A23V2250/0628 ,  A23V2250/0632 ,  A23V2250/628 ,  A23V2250/0654 ,  A23V2250/0638 ,  A23V2250/606 ,  A23V2250/70 ,  A23V2250/5062 ,  A23V2250/506

摘要： Methods and nutritional or pharmaceutical compositions for promotion of muscle protein synthesis or controlling tumor-induced weight loss, such as cancer cachexia.

公开(公告)号：EP1527343A2

公开(公告)日：2005-05-04

申请号：EP03766324.2

申请日：2003-07-28

申请人： Novartis AG ,  Novartis Pharma GmbH

发明人： LI, Sau Wei,Novartis Horsham Research Centre ,  POLL, Christopher T.,Novartis Horsham Res. Ctr. ,  WESTWICK, John,Novartis Horsham Research Centre ,  GOSLING, Martin,Novartis Horsham Research Centre

IPC分类号： G01N33/566 ,  G01N33/68 ,  A61K39/00 ,  A61K48/00 ,  A61K31/4174

CPC分类号： G01N33/6872 ,  G01N2500/04

摘要： The invention relates to an assay for substances that modulate the activity of a polypeptide encoded human transient receptor potential 6 gene (TRPC6). The assay involves combining a candidate substrate substance with the polypeptide and measuring the effect of the candidate substance on the activity of said polypeptide. Such substances may be used in the preparation of pharmaceuticals for treating inflammatory diseases, particularly those associated with leukocytes.

摘要翻译： 本发明涉及用于调节多肽编码的人瞬时受体电位6基因（TRPC6）活性的物质的测定。 该测定包括将候选底物物质与多肽组合并测量候选物质对所述多肽活性的影响。 这些物质可用于制备治疗炎性疾病的药物，特别是与白细胞有关的炎症性疾病。

公开(公告)号：EP1519719A1

公开(公告)日：2005-04-06

申请号：EP03738107.6

申请日：2003-07-01

申请人： Novartis AG

发明人： ATILLASOY, Ercem ,  BRADFORD, Steven ,  DAY, Lynn ,  PFISTER, Pascal ,  TAVAKKOL, Amir

IPC分类号： A61K31/135 ,  A61K31/137

CPC分类号： A61K31/137 ,  A61K31/135

摘要： The invention provides a method of treating chronic rhinosinusitis such as allergic fungal sinusitis comprising daily oral administration of a composition comprising from more than 500 mg to about 800 mg, preferably about 625 mg or 725 mg terbinafine base equivalent as hydrochloride, or a molar equivalent in other acid addition salt or free base form, for a duration effective to reduce the symptoms of, or eliminate chronic rhinosinusitis; it further concerns the use of terbinafine in the manufacture of a corresponding medicament, and packs containing a plurality of corresponding compositions and medicaments.

公开(公告)号：EP1492780A1

公开(公告)日：2005-01-05

申请号：EP03720412.0

申请日：2003-04-02

申请人： Novartis AG ,  Novartis Pharma GmbH

发明人： COPPOLA, Gary, Mark ,  DAVIES, John, William ,  JEWELL, Charles, Francis, Jr. ,  LI, Yu-Chin ,  WAREING, James, Richard ,  SPERBECK, Donald, Mark ,  STAMS, Travis, Mathew ,  TOPIOL, Sidney, Wolf ,  VLATTAS, Isidoros

IPC分类号： C07D285/10 ,  A61K31/433 ,  A61P3/10 ,  C07D417/06

CPC分类号： C07D285/10 ,  C07D417/06 ,  C07D417/10 ,  C07K5/06078

摘要： Compounds of the formula (I) provide pharmacological agents which are inhibitors of PTPases, in particular, the compounds of formula (I) inhibit PTP-1 B and TC PTP, and thus may be employed for the treatment of conditions associated with PTPase activity. The compounds of the present invention may also be employed for inhibition of other enzymes with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels. The compounds of the present invention may also be employed in the treatment, prevention or control of a number of conditions that accompany Type 2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat or prevent cancer, osteoporosis, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

公开(公告)号：EP1476565A2

公开(公告)日：2004-11-17

申请号：EP03709701.1

申请日：2003-02-07

申请人： Novartis AG ,  Novartis Pharma GmbH

发明人： ASSELBERGS, Fredericus, Alphonsus, Maria ,  ATADJA, Peter, Wisdom ,  HALL, Jonathan ,  KINZEL, Bernd

IPC分类号： C12Q1/44

CPC分类号： G01N33/57484 ,  C12Q1/44 ,  G01N2500/00

摘要： The invention relates to the use of Fra -1 levels as a marker for HDAC inhibition. Also disclosed are in vivo and in vitro methods for screening a compound for HDAC inhibitory activity, as well as methods for monitoring the therapeutic efficacy of an HDAC inhibitor in a subject in vivo and for determining resistance to an HDAC inhibitor in vitro or in vivo.